VKTX241213C49500
- 0.15
- -0.40-72.73%
Viking Therapeutics Newsroom
Promising Prospects for Viking Therapeutics' VK2735 in Obesity Treatment: A Buy Rating With $125 Price Target
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Piper Sandler Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $74
Piper Sandler Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $74
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Viking Therapeutics Analyst Ratings
B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $164
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $118
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Viking Therapeutics (VKTX) Gets a Buy From Truist Financial
Promising Phase 1 Results for Viking Therapeutics' VK2735: Analyst Recommends Buy Rating
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $125